Scarica l'app Stockscreener
73.09
1.18%
-0.87
Pre-mercato:
73.74
0.65
+0.89%
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Liquidity Mapping Around (IONS) Price Events - Stock Traders Daily
IONS Reiterated by TD Cowen -- Price Target Maintained at $108 - GuruFocus
Ionis Pharmaceuticals Stock (US46120E6023): Analyst updates keep biotech in focus - AD HOC NEWS
Insider plans 8,000-share sale at IONS (NASDAQ: IONS) on 06/15/2026 - Stock Titan
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
IONS (IONS) files Form 144 listing option-exercise shares on Nasdaq - Stock Titan
Ionis Highlights Positive Long-Term Olezarsen Data in Hypertriglyceridemia - TipRanks
Olezarsen liver fat study data highlighted by Ionis (NASDAQ: IONS) - Stock Titan
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy - MSN
Ionis Pharmaceuticals touts $3B TRYNGOLZA opportunity, pipeline readouts at conference - MSN
Franklin Resources Inc. Has $104.53 Million Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Norges Bank Invests $25.33 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Sells 21,021 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Adds Veteran Leader to Board - The Globe and Mail
Ionis Pharmaceuticals, Inc. (IONS) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IONS) 2026-06-08 - Seeking Alpha
Ionis Pharmaceuticals (NASDAQ: IONS) director Peter Reikes files baseline Form 3 - Stock Titan
Ionis Pharmaceuticals adds Ludwig Hantson to board By Investing.com - Investing.com South Africa
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors - Lelezard
Ionis Pharmaceuticals adds Ludwig Hantson to board - Investing.com
Ionis’ ASO for ultra-rare neurological disorder awaits FDA’s decision - BioXconomy
CenterBook Partners LP Acquires Shares of 153,949 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital World Investors Has $1.42 Billion Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis updates time for fourth quarter and full year 2025 financial results webcast - Business Wire
Long term debt to total equity ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Debt to assets ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Price to book ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Ionis Pharmaceuticals (IONS) Edges Lower Amidst Sector Headwinds; Key Support Levels in FocusVanna Flow - newsline.com
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals, Inc. Balance Sheet – XETR:ISI - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – XETR:ISI - TradingView
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates - Yahoo Finance
TD Asset Management Inc Trims Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires 19,554 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Key facts: Ionis licenses salanersen to Biogen; sees >$7B peak - TradingView
Why (IONS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
Ionis Pharmaceuticals Announces New Data on Olezarsen for sHTG T - GuruFocus
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses - standard-journal.com
Ionis Pharmaceuticals director sells $605,360 in stock - Investing.com UK
Ionis Pharmaceuticals director sells $605,360 in stock By Investing.com - Investing.com Canada
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Ionis Pharmaceuticals Insider Sold Shares Worth $605,360, According to a Recent SEC Filing - marketscreener.com
Geode Capital Management LLC Boosts Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
IONS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $125 - GuruFocus
[144] IONIS PHARMACEUTICALS INC SEC Filing - Stock Titan
H.C. Wainwright reiterates Ionis stock rating on hepatitis B data By Investing.com - Investing.com Canada
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A High-Stakes Biotech Play with 31.92% Upside Potential - DirectorsTalk Interviews
IONS Q1 earnings & sales beat, stock rises on raised '26 view - MSN
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report? - Yahoo Finance
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):